Contributing Editors: Amit Kumar, Ph.D and Robert Berman
For nearly 45 years, the national dialogue, when it comes to cancers, has remained essentially the same. We have been racing for the cure, praying for the cure, searching for the cure, researching for the cure, raising money for the cure, funding the cure, and developing treatments for the cure. Curing cancer has become the “national cancer objective”.…Continue
Added by Editorial Team on March 11, 2016 at 9:30am — No Comments
Senior leaders from more than a dozen biopharmaceutical companies came together today with world-class academic clinicians from four leading cancer centers, representatives from oncology non-profits, the FDA, and other key stakeholder organizations to advance the most promising avenues for curing cancer: accelerating the development of investigational drug combination therapies of two or more investigational treatments which may hold great promise for cancer patients.
Added by Editorial Team on March 7, 2016 at 2:00pm — No Comments
Located just behind the stomach, measuring about 6 inches long and less than 2 inches wide, is an organ called the pancreas. Shaped like a fish with a wide head, a tapering body and a small, pointed tail, the pancreas contains 2 different types of glands - exocrine and endocrine - which are a vital part of the digestive system and a critical controller of blood sugar levels.
Tumors of the pancreas are malignant neoplasms arising in the pancreas. Because of its 'hidden' location, these…Continue
Added by Editorial Team on February 1, 2016 at 10:00pm — No Comments
By Sonia Portillo, Medical Writer
In the current oncology therapeutics market, an estimated $45 billion is brought in through cytogenic therapeutics. Of that amount, 70% is attributed to generic cytostatics, which are largely dominated by paclitaxel-based products Taxol and Abraxane® (Celgene). In fact, before going generic, Taxol brought in around 1.6 billion dollars annually, and it was used for 16 cancer indexes. Just last…Continue
Added by Editorial Team on January 22, 2016 at 8:30pm — No Comments
Although the United States has curtailed the use of asbestos-containing products in residential and commercial construction, the effects of asbestos exposure are still a major concern. Additionally, there are several places around the world where asbestos exposure is still quite high. Asbestos occurs naturally in the ground in countries like Turkey.…Continue
Added by Editorial Team on December 18, 2015 at 9:00am — No Comments
Although based on early data, study findings suggest an association between the Affordable Care Act Dependent Coverage Expansion provision and cervical cancer stage at diagnosis and receipt of fertility-sparing treatment among young women age 21 to 25 years, but not among women aged 26 to 34 years, according to a study, supported by the Intramural Research Department of the American Cancer Society, published in the November 24 issue of JAMA.
In September 2010,…Continue
Added by Editorial Team on November 24, 2015 at 10:30am — No Comments
Biomedical engineers at Texas A&M University, committed to solving the world’s greatest health problems through the exploration of new ideas, integrated research and innovation, have developed a new technology focusing on a new synthetic material that’s strong enough to fill gaps in bone while stimulating new bone growth that could advance the grafting treatments needed by people suffering from bone cancer and other bone defects.
"This material serves as a biodegradable scaffold…Continue
Added by Editorial Team on November 19, 2015 at 9:00am — No Comments
Ludwig Cancer Research, an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 40 years, and the Cancer Research Institute (CRI), the world's only non-profit organization dedicated exclusively to transforming cancer patient care by advancing scientific efforts to develop new and effective immune system-based strategies to prevent, diagnose, treat, and…Continue
Added by Editorial Team on November 18, 2015 at 4:00pm — No Comments
The Joint Center for Cancer Precision Medicine, a collaborative initiative to create “precision medicine treatment pathways” for patients with advanced cancers and to speed the development of personalized therapies has been established as part of a collaboration between the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, and the Broad Institute of MIT and Harvard.
The new Joint Center brings together expertise and resources in state-of-the-art…Continue
Added by Editorial Team on November 17, 2015 at 3:00pm — No Comments
Marketing of prescription medications and medical devices directly to consumers has, for many years, been the focus of considerable - ongoing - debate. Proponents argue that Direct-to-Consumer or DTC advertisingis an important tool to informs consumers - as well as patients - about important, treatable health conditions. It encourages and…Continue
Added by Editorial Team on November 17, 2015 at 9:00am — No Comments
Lung cancer is the leading cause of cancer death among both men and women, accounting for about one-third of all cancer deaths, more than breast, prostate and colorectal cancers combined. Lung cancer has a five-year survival rate that is less than 20%. Approximately 85% of all lung cancers in the U.S. are Non-small Cell Lung Cancers (NSCLC). Approximately 10% to 15% of these are EGFR mutation-positive.
Over the past decade, small-molecule EGFR tyrosine kinase…Continue
Added by Editorial Team on November 16, 2015 at 11:30am — No Comments
Earlier today Oryzon Genomics, a clinical stage biopharmaceutical company based in Barcelona (Spain) leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced the dosing of the first patient in the extension cohort (Part 2) of its ORY-1001 Phase I clinical trial. The trial will take place in 10 centers in Spain, UK and France.
ORY-1001 is a highly selective and potent LSD1 inhibitor which is…Continue
Added by Editorial Team on November 10, 2015 at 4:00pm — No Comments
When bladder cancer patients are well-informed by their physicians, they acknowledge that tobacco use was likely the cause of their disease. The finding comes from a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. Patients with such knowledge may be more motivated to quit smoking, which could help prolong their lives.
According the American Cancer Society, in the United States about 74,000 new cases of bladder…Continue
Added by Peter Hofland, PhD on November 10, 2015 at 10:00am — No Comments
Results from a phase I/II dose-escalation and dose-expansion study of epacadostat (incb024360; Incyte Corporation)*, a potent, selective inhibitor of indoleamine 2,3-dioxygenase 1 (also known as IDO1), in combination with pembrolizumab (Keytruda®; formerly known as MK-3475 and lambrolizumab; Merck & Co., Inc) were reported earlier today during the 30th Anniversary Annual Meeting Late-Breaking…Continue
Added by Editorial Team on November 6, 2015 at 5:30pm — No Comments
Synovial sarcomas are rare and aggressive soft tissue sarcomas developing in connective tissues, general near joints. The condition may, in the early stages of the disease, not cause noticeable signs or symptoms. Frequently spreading from their original location, synovial sarcomas are often difficult to treat with standard therapies.
One potentially new treatment involves genetically modifying immune cells which are designed to recognize and attack cancer cells. Giving these…Continue
Added by Editorial Team on November 5, 2015 at 1:30pm — No Comments
A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.
The findings, published in the November 5, 2015 online issue of Journal of the…Continue
Added by Editorial Team on November 5, 2015 at 11:00am — No Comments
By Carolyn Brent, MBA, Contributing Author
It’s a sad reality that, as we age, we become less independent than we once were – but for most blessed with longevity, it’s inevitable. With an estimated 13 million baby boomers throughout the U.S. caring for elderly parents, throngs of adult caregivers struggle with determining if their parent is fit to remain living…Continue
Added by Editorial Team on November 4, 2015 at 7:30pm — No Comments
The concept of viruses to treat human malignancy is not new. In the mid 1890's William B. Coley, a New York surgeon, noted that infections could result in an impressive tumor response. Not much later, Louis Pasteur observed that patients with cervical cancer showed regression after being vaccinated with an attenuated rabies virus. By the mid-twentieth century scientists understood that some viruses were able to invade almost any cell in the body and kill it. However, it would not…Continue
Added by Editorial Team on October 28, 2015 at 6:30pm — No Comments
By John Leifer - Contributing editor
Providers of cancer treatment and therapeutics have learned to carefully hone their rhetoric so that it conveys a socially appropriate sense of altruism. Yet, beneath this thin veneer exists a motivation every bit as powerful as saving lives – reaping billions of dollars in profit. That’s what’s at stake in the…Continue
Added by Editorial Team on October 16, 2015 at 10:30am — No Comments
Earlier today Incyte Corporation and Merck & Co., Inc , known as MSD outside the United States and Canada, announced that they have agreed to expand the ongoing clinical trial collaboration to include a Phase III study evaluating the combination of epacadostat, Incyte’s investigational selective Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, with pembrolizumab (Keytruda®)*, Merck’s anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma.
Added by Editorial Team on October 13, 2015 at 9:30am — No Comments